This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Granados, J. Articles by Alarcón-Segovia, D. Search for Related Content PubMed PubMed Citation Articles by Granados, J. Articles by Alarcón-Segovia, D. Social Bookmarking                         What's this?

Relationship of anticardiolipin antibodies and antiphospholipid syndrome to HLA-DR7 in Mexican patients with systemic lupus erythematosus (SLE)

Department of Immunology and Rheumatology, Instituto Nacional de la Nutrición Salvador Zubirán, Mexico City, Mexico

G. Vargas-Alarcón

Department of Immunology and Rheumatology, Instituto Nacional de la Nutrición Salvador Zubirán, Mexico City, Mexico

C. Drenkard

Department of Immunology and Rheumatology, Instituto Nacional de la Nutrición Salvador Zubirán, Mexico City, Mexico

F. Andrade

Department of Immunology and Rheumatology, Instituto Nacional de la Nutrición Salvador Zubirán, Mexico City, Mexico

H. Melín-Aldana

Department of Immunology and Rheumatology, Instituto Nacional de la Nutrición Salvador Zubirán, Mexico City, Mexico

J. Alcocer-Varela

Department of Immunology and Rheumatology, Instituto Nacional de la Nutrición Salvador Zubirán, Mexico City, Mexico

D. Alarcón-Segovia

Department of Immunology and Rheumatology, Instituto Nacional de la Nutrición Salvador Zubirán, Mexico City, Mexico

We studied IgG and IgM anticardiolipin antibodies (aCL) by an ELISA method in 80 Mexican systemic lupus erythematosus (SLE) patients and 378 of their first degree relatives. Sixty five percent of SLE patients and 16% of their relatives were positive for aCL. We also determined allele and haplotype frequencies of Major Histocompatibility Complex (MHC) genes (classes I, II and III) in both patients and relatives. MHC allele and haplotype frequencies of aCL positive and negative individuals were compared to those of normal ethnically matched controls. SLE patients with aCL had statistically significant increased corrected frequencies of HLA-DR3 (pC = 0.04, RR = 2.78); DR7 (pC = 0.005), RR = 3.42) and DQ2 (pC = 0.003, RR = 2.58) antigens. Their first degree relatives positive for aCL also had increased frequency of HLA-DR7 but it did not remain significant after correcting the P value. On the other hand, SLE patients negative for aCL had a moderate increased frequency of DR3 and DQ2 but not of DR7. These results suggest that DR7 associates with the presence of aCL. The distribution of MHC alleles in SLE patients positive for aCL resembles that found in their aCL positive first degree relatives.

Since the presence of the antibody is not sufficient to predict a clinical outcome, we studied those patients with reliable clinical data regarding the presence of the antiphospholipid syndrome (aPLS). SLE patients with aPLS had significantly increased frequency of DR7 (pC = 0.004), as did those with probable aPLS (pC = 0.05), while the frequency of DR7 in SLE patients in the doubtful or negative aPLS categories was no different from normal controls.

These data support a possible role of DR7 in the development of aCL in SLE patients and their relatives and suggest a contribution of this class II MHC antigen to the development of aPLS within SLE.

Key Words: anticardiolipin antibodies • antiphospholipid syndrome • systemic lupus erythematosus • major histocompatibility complex • antiphospholipid antibodies • autoimmunity

Lupus, Vol. 6, No. 1, 57-62 (1997)
DOI: 10.1177/096120339700600108


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. P. Greco, A. M. Conti-Kelly, T. Greco Jr, R. Doyle, E. Matsuura, J. R. Anthony, and L. R. Lopez Newer Antiphospholipid Antibodies Predict Adverse Outcomes in Patients With Acute Coronary Syndrome Am J Clin Pathol, October 1, 2009; 132(4): 613 - 620. [Abstract] [Full Text] [PDF]

				N J McHugh, P Owen, B Cox, J Dunphy, and K Welsh MHC class II, tumour necrosis factor {alpha}, and lymphotoxin {alpha} gene haplotype associations with serological subsets of systemic lupus erythematosus Ann Rheum Dis, April 1, 2006; 65(4): 488 - 494. [Abstract] [Full Text] [PDF]

				I Uthman and M Khamashta Ethnic and geographical variation in antiphospholipid (Hughes) syndrome Ann Rheum Dis, December 1, 2005; 64(12): 1671 - 1676. [Abstract] [Full Text] [PDF]

				M. A. Ozturk, I. C. Haznedaroglu, M. Turgut, and H. Goker Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia Clinical and Applied Thrombosis/Hemostasis, April 1, 2004; 10(2): 89 - 126. [Abstract] [PDF]

				J. H. Rand Molecular Pathogenesis of the Antiphospholipid Syndrome Circ. Res., January 11, 2002; 90(1): 29 - 37. [Abstract] [Full Text] [PDF]

				M Weber, G Hayem, M DeBandt, E Palazzo, S Roux, M-F Kahn, and O Meyer The family history of patients with primary or secondary antiphospholipid syndrome (APS) Lupus, May 1, 2000; 9(4): 258 - 263. [Abstract] [PDF]

				L M Vila, A M Mayor, A H Valentin, M Garcia-Soberal, and S Vila Clinical and immunological manifestations in 134 Puerto Rican patients with systemic lupus erythematosus Lupus, May 1, 1999; 8(4): 279 - 286. [Abstract] [PDF]

				M Schutt, H Kluter, M Hagedorn-Greiwe, H L Fehm, and G J Wiedemann Familial coexistence of primary antiphospholipid syndrome and factor VLeiden Lupus, March 1, 1998; 7(3): 176 - 182. [Abstract] [PDF]